2017 | Page 2 of 4 | サターラ

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

Certara2017年8月24日

Brochure

Investigational Drug Gap Analysis

As the process of drug development has increased in cost and complexity, Certara has developed…

Certara2017年8月14日

Press Coverage

Clinical Pharmacology—The Quarterback of Drug Development

Clinical pharmacology accounts for about 50% of a drug label. Its scope ranges from facilitating…

Certara2017年8月14日

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Certara2017年8月1日

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Certara2017年7月15日

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

Certara2017年7月1日

Poster

Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model

Certara2017年6月6日

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

Certara2017年6月1日

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

Certara2017年6月1日

Blog

Mind the Gap: 臨床薬理学のギャップ分析におけるベストプラクティス

Do you get anxious about taking tests? Many people do because they want to show…

Certara2017年5月25日

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software